Joshua Phillips is a Managing Partner of Catalyst Health Ventures. Josh led Catalyst’s investments in Novazyme Pharmaceuticals, Inc. (acquired by Genzyme Corp. NYSE:SNY), BioTrove, Inc. (acquired by Life Technologies Corp. NASDAQ:LIFE), Biocius Life Sciences, Inc. (acquired by Agilent Technologies, Inc. NYSE:A), Vortex Medical, Inc. (acquired by Angiodynamics, NASDAQ: ANGO), Allegro Diagnostics, Inc. (acquired by Veracyte, NASDAQ: VCT), SevenOaksBiosciences (Acquired by Medline Industries), Pavilion Medical Innovations, Sera Prognostics and Cruzar Medsystems. He is a Director at Pavilion Medical Innovations, Sera Prognostics, Cruzar Medsystems, Saphena Medical, Conformal Medical and Brixton BioSciences. He was past Chairman of BioTrove, past Director of Biocius Life Sciences and past observer to Novazyme Pharmaceuticals, Inc.
Prior to joining Catalyst, Josh was a Manager at the Lucas Group, a boutique strategy-consulting firm, where he led engagements advising healthcare, life science, and technology-based companies. In 1990, Josh co-founded, managed and built a new business unit at Russelectric Inc., a privately held engineering technology firm. In five years, the business achieved annual sales in excess of $5 million and employed 15 engineers and technicians. Josh previously held project and engineering management positions at Pratt & Whitney Aircraft focused on the integration of hardware and software for the control system of the USAF F-22 fighter engine.
Josh received a B.E. in Electrical Engineering and Mathematics from Vanderbilt University and an M.B.A. from the Harvard Business School.